Technical Analysis for VKTX - Viking Therapeutics, Inc.

Grade Last Price % Change Price Change
D 11.22 2.75% 0.30
VKTX closed up 2.75 percent on Thursday, September 28, 2023, on 1.52 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish 2.75%
Lower Bollinger Band Walk Weakness 2.75%
Wide Bands Range Expansion 2.75%
Below Lower BB Weakness 2.75%
Lower Bollinger Band Touch Weakness 2.75%
Oversold Stochastic Weakness 2.75%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 9 hours ago
Up 2% about 10 hours ago
60 Minute Opening Range Breakout about 10 hours ago
1.5x Volume Pace about 12 hours ago
60 Minute Opening Range Breakdown about 13 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Viking Therapeutics, Inc. Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which has completed Phase I trial for the treatment of cancer cachexia, a disease characterized by an uncontrolled decline in muscle mass. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as other preclinical programs for metabolic diseases and anemia. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Disease Diabetes Alcohol Medication Treatment Of Cancer Lipid Steatohepatitis Hepatitis Metabolic Disease Thyroid Anemia Non Alcoholic Fatty Liver Disease Geriatrics Dyslipidemia Rehabilitation Medicine Cachexia Endocrine Disorders Endocrine Disease

Is VKTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 25.7199
52 Week Low 2.68
Average Volume 1,754,898
200-Day Moving Average 14.61
50-Day Moving Average 14.05
20-Day Moving Average 13.83
10-Day Moving Average 12.78
Average True Range 0.79
RSI (14) 29.08
ADX 28.97
+DI 10.93
-DI 38.54
Chandelier Exit (Long, 3 ATRs) 13.99
Chandelier Exit (Short, 3 ATRs) 13.04
Upper Bollinger Bands 16.67
Lower Bollinger Band 10.98
Percent B (%b) 0.04
BandWidth 41.21
MACD Line -0.81
MACD Signal Line -0.44
MACD Histogram -0.3653
Fundamentals Value
Market Cap 818.52 Million
Num Shares 73 Million
EPS -0.35
Price-to-Earnings (P/E) Ratio -31.78
Price-to-Sales 0.00
Price-to-Book 1.92
PEG Ratio -0.03
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.20
Resistance 3 (R3) 12.12 11.72 12.03
Resistance 2 (R2) 11.72 11.47 11.76 11.98
Resistance 1 (R1) 11.47 11.32 11.60 11.55 11.92
Pivot Point 11.07 11.07 11.13 11.11 11.07
Support 1 (S1) 10.82 10.82 10.95 10.90 10.52
Support 2 (S2) 10.42 10.67 10.46 10.46
Support 3 (S3) 10.17 10.42 10.41
Support 4 (S4) 10.25